Atlas Arteria Group (ASX:ALX) and Telix Pharmaceuticals Ltd (ASX:TLX) shares are two of four dropping lower on Friday…
The post Why Atlas Arteria, Cochlear, Telix, & Treasury Wine shares are dropping lower appeared first on Motley Fool Australia. –
In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to finish the week on a very positive note. The benchmark index is currently up a sizeable 1.6% to 5,971.5 points.
Four shares that have failed to follow the market higher today are listed below. Here’s why they are dropping lower:
The Atlas Arteria Group (ASX: ALX) share price is down almost 3% to $6.11. This morning the toll road operator’s shares traded ex-dividend for its 11 cents per share interim dividend. In addition to this, rising coronavirus cases in Europe appear to be weighing on its shares. Atlas Arteria has a collection of toll roads in France which could experience subdued traffic volumes in the near term if Europe goes back into lockdown.
The Cochlear Limited (ASX: COH) share price is down almost 1% to $200.65. Earlier this week UBS reaffirmed its sell rating and $175.00 price target on this hearing solutions company’s shares. Its analysts believe that the market is expecting too much from Cochlear in respect to sales growth in the coming years.
The Telix Pharmaceuticals Ltd (ASX: TLX) share price has fallen 1.5% to $1.75. This decline appears to be down to profit taking after some strong gains in recent months by the biopharmaceutical company’s shares. For example, prior to today, Telix’s shares were up a massive 115% over the last six months.
The Treasury Wine Estates Ltd (ASX: TWE) share price has dropped almost 1% to $9.00. Investors have been selling the wine company’s shares despite it being subject to a positive broker note out of Credit Suisse yesterday. The broker has upgraded Treasury Wine’s shares to an outperform rating with a $12.30 price target. This price target implies potential upside of almost 37% for its shares over the next 12 months. Clearly some investors aren’t as bullish on its prospects.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- The Aussie dollar at a critical juncture and could turn fortunes for these ASX stocks
- Top brokers name 3 ASX shares to sell today
- Why Iron Road, Nuchev, Telix, & Treasury Wine shares are pushing higher today
- Telix (ASX:TLX) share price charges higher on FDA update
- Forget BrainChip (ASX:BRN) and buy and hold these outstanding ASX shares
James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended Treasury Wine Estates Limited. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why Atlas Arteria, Cochlear, Telix, & Treasury Wine shares are dropping lower appeared first on Motley Fool Australia.